high return mutual funds  - Fast-Track Your Wealth Growth
high return mutual funds  - Fast-Track Your Wealth Growth
high return mutual funds  - Fast-Track Your Wealth Growth
high return mutual funds  - Fast-Track Your Wealth Growth
high return mutual funds  - Fast-Track Your Wealth Growth
high return mutual funds  - Fast-Track Your Wealth Growth
high return mutual funds  - Fast-Track Your Wealth Growth
high return mutual funds  - Fast-Track Your Wealth Growth

high return mutual funds - Fast-Track Your Wealth Growth

₹1463

high return mutual funds ✌️【Self-Scheduling】✌️Start with ₹500 and earn steady, high returns every month!

quantity
Add to Wishlist
Product Description

high return mutual funds ✌️【Self-Scheduling】✌️Start with ₹500 and earn steady, high returns every month!

high return mutual funds ✌️【Self-Scheduling】✌️Start with ₹500 and earn steady, high returns every month!Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

high return mutual funds ✌️【Self-Scheduling】✌️Invest ₹500 today and see your wealth grow with our safe, reliable platform.We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

high return mutual funds ✌️【Self-Scheduling】✌️Invest ₹500 and experience guaranteed monthly profits. Start now!The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

high return mutual funds ✌️【Self-Scheduling】✌️Get high returns with just ₹500. Invest today and see your wealth grow!The underperformance persists despite a 22.high return mutual funds Reliable Investment Options with High Returns

Related Products